Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction - insights from the IAMI trial
Authors' conclusion
The beneficial effect of influenza vaccination on adverse cardiovascular events may be enhanced in patients with NSTEMI compared to those with STEMI.
Study context
- Population
- Patients with STEMI or NSTEMI after myocardial infarction (MI)of 2,571 randomised · Patients with STEMI 1,348 · or NSTEMI 1,119
- Participants
- 2,467 patients
- Comparison
- Influenza vaccine vs placebo, by NSTEMI vs STEMI
- Primary endpoint
- All-cause death, MI or stent thrombosis
- Follow-up
- 12 months
Methodological detailsplacebo-controlled, multicentre, 30 centres in 8 countries, Conducted October 1, 2016 to March 1, 2020
- Placebo-controlled
- Multicentre
- 30 centres in 8 countries
- Conducted October 1, 2016 to March 1, 2020
Primary result
As reported in the abstract
All-cause death, MI or stent thrombosis, by MI type
Influenza vaccine vs PlaceboHazard ratio (95% CI)
NSTEMI
0.60(0.39–0.91)
STEMI
0.90(0.54–1.50)
Secondary outcomes
All-cause death, by NSTEMI/STEMI (subgroup) · one year
- NSTEMI: HR
- 0.47 (95% CI 0.28-0.80)
- STEMI: HR
- 0.86 (95% CI 0.43-1.70)
- Risk difference more pronounced in NSTEMI
- interaction P = .028
All-cause death and CV death (key secondary endpoints)
- Similar findings to the primary endpoint
Original publication
Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction - insights from the IAMI trial. Am Heart J. Published 21 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →